 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Aromatase Inhibitor Clinical Trial
|
|
|
|
Phase IV
|
|
|
|
0412-14
UO1-GM61373-06, NCT00228956
|
|
| |
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer
|
|
|
|
Phase IV
|
|
|
|
0501-37
NCT00352872
|
|
| |
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
|
|
|
Phase III, Phase II
|
|
|
|
20050113
NCT00243685
|
|
| |
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
0120070323
NCT00698971
|
|
| |
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
|
|
|
|
Phase III
|
|
|
|
SWOG-S0221
S0221, NCT00070564
|
|
| |
Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer
|
|
|
|
Phase III
|
|
|
|
IBCSG-27-02
BIG-1-02, EU-20320, NCT00074152, NSABP-B-37, EUDRACT-2005-001484-64
|
|
| |
A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients With Advanced Breast Cancer
|
|
|
|
Phase III
|
|
|
|
DOXIL-BCA-3001
NCT00091442
|
|
| |
Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer
|
|
|
|
Phase III
|
|
|
|
SWOG-S0307
NCCTG-SWOG-S0307, ECOG-SWOG-S0307, NSABP-SWOG-S0307, CALGB-SWOG-S0307, CAN-NCIC-SWOG-S0307, S0307, NCT00127205
|
|
| |
Nexium Study To Suppress Nausea During Chemotherapy
|
|
|
|
Phase III
|
|
|
|
H-16348
Nexium Study, NCT00206440
|
|
| |
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
|
|
|
|
Phase III
|
|
|
|
ACOSOG-Z1031
CALGB-ACOSOG-Z1031, ACOSOG-Z1031, SDC1, NCT00265759
|
|
